SFJ and Merck KGaA are collaborating on the development of Abituzumab, a novel monoclonal antibody in first-line metastatic colon cancer in combination with Erbitux and chemotherapy in patients with RAS wild-type left-sided tumors with high ανβ6 integrin expression

LocationPleasanton, California
CEORobert DeBenedetto
Partner Shelley Chu , Ken Haas
Websitewww.sfj-pharma.com